Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference.
The event is virtual on February 25, 2026 with a presentation at 3:20 PM ET; a webcast link will be provided for investors.
Details
News Market Reaction – CRBP
On Feb 12, the day this news came out, CRBP closed 2.76% above the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Conference edition
- 36th Annual
- Oppenheimer Healthcare Life Sciences Conference
- Conference date
- February 25, 2026
- Virtual Oppenheimer Healthcare Life Sciences Conference
- Presentation time
- 3:20 p.m. ET
- Scheduled time for corporate overview presentation
Historical Context
-
Announced CEO presentation at J.P. Morgan Healthcare conference with webcast access.
-
Reported Phase 1a CRB-913 obesity data with favorable safety and early weight loss.
-
Outlined timing for Phase 1a CRB-913 obesity data release and webcast details.
-
Q3 2025 results, CRB-701 efficacy data, cash raise, and runway into 2028.
-
Planned participation in multiple healthcare investor conferences with webcasts.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026.
36th Annual Oppenheimer Healthcare Life Sciences Conference
Format: Virtual presentation and one-on-one investor meetings
Date: February 25, 2026
Presentation Time: 3:20pm Eastern Time
Webcast Link: Click Here
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.